Skip to main content
. 2021 Apr 9;16(4):e0248984. doi: 10.1371/journal.pone.0248984

Fig 5.

Fig 5

(a) Complete connectivity network of ELF4 to the drug targets ABL1 and SRC minded from the literature and various protein-protein interaction databases. (b) Pruned network showing only the most highly relevant interaction between ELF4, ABL1 and SRC. Reactome pathways most significantly altered in high-ELF4 tumours belonging to (c) pancreatic adenocarcinomas, (d) lung adenocarcinomas, (e) invasive breast carcinomas, and (f) kidney renal clear cell carcinoma. Refer to S4 File for the complete list of Reactome pathways enriched in these tumours.